The American Society of Clinical Oncology (ASCO) today announced the Health Policy Leadership Development Program Fellows for the 2019-2020 class. Wendy Allen-Rhoades, MD, of Baylor College of Medicine, and Laura LaNiel Tenner, MD, MPH, of The Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, will spend the next year developing leadership skills and healthcare policy expertise. During their fellowship, Dr. Allen-Rhoades and Dr. Tenner will participate in ASCO efforts to shape cancer-related policies that directly affect individuals with cancer and the oncology practice environment.
ALEXANDRIA, Va. — Positive findings from fully enrolled cohorts in non-small cell lung cancer and metastatic breast cancer from the American Society of Clinical Oncology, Inc.’s (ASCO) Targeted Agent and Profiling Utilization Registry (TAPUR™) Study will be presented in poster sessions at the 2019 ASCO® Annual Meeting. In addition, the study is being expanded to include patients with active brain metastases and three new drug therapies. Pharmaceutical company Boehringer Ingelheim has also joined the study and, later this year, will provide afatinib (Gilotrif®) to participants who enroll in a tissue-agnostic cohort of patients with an NRG1 gene fusion. That same month, the TAPUR Study also will add two new drugs from existing pharmaceutical company collaborators: abemaciclib (Verzenio®, Eli Lilly and Company) and talazoparib (Talzenna®, Pfizer).
“ASCO strongly supports this strong, bipartisan bill that would raise the federal age for purchasing tobacco products, electronic cigarettes, and alternative nicotine products from 18 to 21 nationwide. This legislation represents an important federal policy change needed to address the ongoing public health epidemic from tobacco use in the United States.
The American Society of Clinical Oncology (ASCO) applauds the Centers for Medicare & Medicaid Services (CMS) for listening to ASCO and other stakeholders by not finalizing a proposal that would have significantly impacted access to drugs within the Six Protected Classes.
ALEXANDRIA, Va. – In a phase I/IB study of 29 patients, age 4.9 months to 20 years, with rare central nervous system tumors, neuroblastoma, or other solid tumors, responses to entrectinib, a novel targeted treatment, were seen in 12 of the 28 evaluable patients. The 12 pediatric patients who experienced a response to therapy had fusions in NTRK1/2/3, ROS1, or ALK genes (11 patients) or an ALK mutation (1 patient). The study will be presented at the upcoming 2019 ASCO Annual Meeting in Chicago.
ALEXANDRIA, Va. – At the launch of the National Cancer Institute-Children’s Oncology Group Pediatric Molecular Analysis for Therapy Choice (NCI-COG Pediatric MATCH) trial in 2017, it was estimated that tumor sequencing in children, adolescents, and young adults with treatment-refractory cancers – cancers that do not respond to treatment– would identify genetic alterations that matched an investigational targeted therapy in 10% of study participants. An interim analysis of more than 400 patients screened has revealed the match rate appears to be significantly higher, with 24% of participants eligible to receive treatment with at least one drug being tested in the trial. The first update on the study will be presented at the upcoming 2019 ASCO Annual Meeting in Chicago.
ALEXANDRIA, Va. – The federally funded Women’s Health Initiative (WHI) clinical trial of dietary modification in nearly 49,000 postmenopausal women with no previous history of breast cancer reported that women who followed a balanced diet that was low in fat and included daily servings of fruits, vegetables, and grains had a 21% lower risk of death from breast cancer than women in the control group who continued their normal diet, which was higher in fat overall. This is the first large, randomized clinical trial to show that diet can reduce the risk of dying from breast cancer. The study will be presented at the upcoming 2019 ASCO Annual Meeting in Chicago.
ALEXANDRIA, Va. — A new study published today in the Journal of Oncology Practice (JOP) reveals the findings of a 2018 American Society of Clinical Oncology (ASCO) Oncology Workforce survey on oncologists’ perceptions and practice behaviors related to diet, physical activity, and weight management in people with cancer — during and after active treatment. The research was also presented today at the American Institute for Cancer Research (AICR) 2019 Research Conference, Diet, Obesity, Physical Activity and Cancer — Beyond the Blueprint.
ALEXANDRIA, Va. – The phase II/III E3A06 randomized clinical trial found that lenalidomide (Revlimid) significantly reduces the risk of smoldering multiple myeloma (SMM) -- a precancerous condition -- from progressing to cancer in patients at moderate or high-risk. Organ damage is typically seen in multiple myeloma, which is a way to differentiate it from SMM. At three years, in 87% (phase II) and 91% (phase III) of people with SMM receiving lenalidomide, the condition did not progress to multiple myeloma compared with 66% of people who did not receive the therapy and were just observed for potential progression (phase III). Observation is the current standard of care. The study will be presented at the upcoming 2019 ASCO Annual Meeting in Chicago.
ALEXANDRIA, Va.—CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO), announced today that CureMD’s Electronic Health Record (EHR) system is the third to be certified by CancerLinQ® after meeting criteria for interoperability and data standardization. This collaboration will streamline access to CancerLinQ® and drive interoperability among EHR systems.
ALEXANDRIA, Va.—CancerLinQ LLC and the International Association for the Study of Lung Cancer (IASLC) have announced a collaboration to expand the specialized expertise informing CancerLinQ®, a health information technology platform, developed by oncologists for oncologists, to enhance and improve the understanding and treatment of cancer. The IASLC will contribute thought leadership and subject matter expertise to CancerLinQ including aspects of clinical practice related to the diagnosis and management of lung cancer, the identification and development of clinical quality measures for thoracic oncology, and other relevant content.
Today, the American Society of Clinical Oncology (ASCO) and the American Cancer Society Cancer Action Network (ACS CAN) will host a joint reception on Capitol Hill for Members of Congress to underscore the two organizations’ shared policy priorities to improve research and cancer care delivery for patients and cancer survivors.
ALEXANDRIA, Va. — The American Society of Clinical Oncology, Inc. (ASCO®) commends the 24 practices that took their standard of care to the next level and achieved Quality Oncology Practice Initiative (QOPI®) Certification in the first quarter of this year. By electing to go through the certification process, these practices have demonstrated their commitment to providing the highest-quality oncology care to their patients, communities, and contemporaries.
ALEXANDRIA, Va. – Cancer experts from around the world will gather to share the latest clinical cancer research impacting patient care at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO). Advances in targeted therapies for pancreatic, prostate, and pediatric cancers, as well as new approaches to overcoming limited access to cancer care are among the topics that will be highlighted in the meeting’s official Press Program.
Today at the National Press Club, the American Society of Clinical Oncology (ASCO) announced a new task force aimed at reducing disparities and improving outcomes for patients and survivors of cancer who live in rural communities. The new “Rural Cancer Care Task Force” will identify opportunities to close the rural cancer care gap and implement strategies to improve rural cancer care in the United States.